The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs by van der Velden, D. L., Hoes, L. R., van der Wijngaart, H., van Berge Henegouwen, J. M., van Werkhoven, E., Roepman, P., Schilsky, R. L., de Leng, W. W. J., Huitema, A. D. R., Nuijen, B., Nederlof, P. M., van Herpen, C. M. L., de Groot, D. J. A., Devriese, L. A., Hoeben, A., de Jonge, M. J. A., Chalabi, M., Smit, E. F., de Langen, A. J., Mehra, N., Labots, M., Kapiteijn, E., Sleijfer, S., Cuppen, E., Verheul, H. M. W., Gelderblom, H., Voest, E. E.

Get full text

Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics by Lips, E. H., Mulder, L., de Ronde, J. J., Mandjes, I. A. M., Vincent, A., Vrancken Peeters, M. T. F. D., Nederlof, P. M., Wesseling, J., Rodenhuis, S.

Get full text

10 Homologous recombination deficiency in breast cancer and association with response to neo-adjuvant chemotherapy by Lips, E.H, Mulder, L, Hannemann, J, Peeters, M.J. Vrancken, van de Vijver, M.J, Wesseling, J, Nederlof, P.M, Rodenhuis, S

Get full text

A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients by Didraga, M. A., van Beers, E. H., Joosse, S. A., Brandwijk, K. I. M., Oldenburg, R. A., Wessels, L. F. A., Hogervorst, F. B. L., Ligtenberg, M. J., Hoogerbrugge, N., Verhoef, S., Devilee, P., Nederlof, P. M.

Get full text

1202 POSTER Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer by Hoogendoorn, W.E, Hollema, H, van Boven, H.H, Bergman, E, De Leeuw-Mantel, G, Platteel, I, Fles, R, Nederlof, P.M, Mourits, M.J.E, van Leeuwen, F.E

Get full text

A tumour with a neuroendocrine and papillary serous component: two or a pair? by van Eeden, S, Nederlof, P M, Taal, B G, Offerhaus, G J A, van Velthuysen, M-L F

Get full text

Comparative genomic hybridization of BRCAX breast tumors by Didraga, M.A, van Beers, E.H, Brandwijk, K, Joosse, S.A, Hogervorst, F.B.L, Wessels, L.F.A, Verhoef, S, Devilee, P, Nederlof, P.M

Get full text

Proteasome: from structure to function by Stock, Daniela, Nederlof, Petra M, Seemüller, Erika, Baumeister, Wolfgang, Huber, Robert, Löwe, Jan

Get full text

Performance of factor IX extended half‐life product measurements in external quality control assessment programs by Nederlof, Angelique, Kitchen, Steve, Meijer, Piet, Cnossen, Marjon, Ali Pour, Nae, Kershaw, Geoffrey, Jennings, Ian, Walker, Isobel, de Maat, Moniek P. M.

Get full text

Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy by Tjin, Esther P M, Krebbers, Gabrielle, Meijlink, Kimberley J, van de Kasteele, Willeke, Rosenberg, Efraim H, Sanders, Joyce, Nederlof, Petra M, van de Wiel, Bart A, Haanen, John B A G, Melief, Cornelis J M, Vyth-Dreese, Florry A, Luiten, Rosalie M

Get full text

ADAMTS‐13 and bleeding phenotype in von Willebrand disease by Boender, Johan, Nederlof, Angelique, Meijer, Karina, Mauser‐Bunschoten, Evelien P., Cnossen, Marjon H., Fijnvandraat, Karin, van der Bom, Johanna G., de Meris, Joke, Laros‐van Gorkom, Britta A.P., van Galen, Karin P.M., Eikenboom, Jeroen, de Maat, Moniek P.M, Leebeek, Frank W.G., Coppens, M., Nieuwenhuizen, L., Tamminga, R.Y.J., Ypma, P.F., Smiers, F.J.W., Beckers, E., Brons, P., Atiq, F.

Get full text